12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Other News

PharmAthene, Siga infectious news

The Delaware Court of Chancery denied Siga's motion for reargument, upholding a September judgment that awarded PharmAthene a 50% share of profits from the sale of Siga's ST-246 smallpox antiviral. PharmAthene said it will...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >